It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2015
  5. Novel Anti-epileptic Drug E Keppra® Filed in Japan for Additional Indication of Adjunctive Therapy for Generalized Tonic-clonic Seizures

March 26, 2015

Otsuka Pharmaceutical Co., Ltd.
UCB Japan Co., Ltd.

Pharmaceuticals

Novel Anti-epileptic Drug E Keppra® Filed in Japan for Additional Indication of Adjunctive Therapy for Generalized Tonic-clonic Seizures

Otsuka Pharmaceutical Co., Ltd. and UCB Japan Co., Ltd. have been engaged in co-development and co-marketing of E Keppra® (generic name: levetiracetam) in Japan. UCB Japan filed an application for a partial change of approval to use levetiracetam in adjunctive therapy with other anti-epileptic drugs for generalized tonic-clonic seizures in adult patients and pediatric patients aged four years and over with generalized epilepsy. The products filed for this indication include E Keppra® Tablets 250 mg and 500 mg, E Keppra® Dry Syrup 50%, and E Keppra® for IV Infusion 500 mg*.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases